Replies to post #62855 on Avid Bioservices Inc (CDMO)

[nh]

Jess, don't forget UTSW in Dallas started the Phase I/II Study of Bavituximab and Sorafenib In Patients With Advanced Hepatocellular Carcinoma this past Dec '10. The phase I aspect is 4 weekly infusions of bavituximab and daily oral sorafenib. The total treatment time for the infusions is one month, one treatment a week.